X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SBCH: Improvement signs… - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 25, 2002

    SBCH: Improvement signs…

    GlaxoSmithKline Consumer Healthcare Ltd. (erstwhile SmithKline Beecham Consumer Healthcare) has posted a much better performance in September quarter, as compared to the June quarter. The malted beverage major reported a 4% growth in topline and finished the quarter with 15% dip in bottomline.

    (Rs m) 3QFY02 3QFY03 Change 9mFY02 9mFY03 Change
    Net sales 2,223 2,319 4.3% 6,190 5,735 -7.4%
    Other Income 99 35 -64.6% 252 115 -54.4%
    Expenditure 1,744 1,844 5.7% 4,837 4,504 -6.9%
    Operating Profit (EBDIT) 478 475 -0.7% 1,353 1,230 -9.1%
    Operating Profit Margin (%) 21.5% 20.5%   21.9% 21.5%  
    Interest (net) 28 21 -23.8% 44 16 -63.2%
    Depreciation 34 93 175.7% 101 161 60.0%
    Profit before Tax 515 395 -23.3% 1,461 1,168 -20.0%
    Tax 233 107 -54.1% 490 364 -25.8%
    Extraordinary items - (48)   - (48)  
    Profit after Tax/(Loss) 283 240 -14.9% 971 757 -22.1%
    Net profit margin (%) 12.7% 10.4%   15.7% 13.2%  
    No. of Shares (eoy) (m) 45.4 45.4   45.4 45.4  
    Diluted Earnings per share* 24.9 21.2   28.5 22.2  
    *(annualised)            
    Current P/e ratio   13.3     12.7  

    The company had posted shocking results in June quarter. SBCH posted a never before 26% decline in the topline in 2QFY03. This resulted in the margins getting squeezed and the company finally finished the quarter with a significant 45% dip in bottomline. The company attributed this dip to an inventory correction as well as delay in commissioning of its new plant in Sonepat, which effectively meant a delay in improvement of efficiencies.

    The company managed to just about stop an operating margin slide, but higher depreciation (Rs 59.4 m) on account of the new Sonepat plant (got commisioned in July 2002), slide in other income, as well as extraordinary expenses towards VRS (Rs 41.4 m) and restructuring, saw profits decline by 15% during 3QFY03. The company has closed its packing operations in Kolkata with affect from August 31, 2002.

    Cost break-up
    (Rs m) 3QFY02 3QFY03 Change 9mFY02 9mFY03 Change
    Stock (5) 197 - (100) 83 -
    RM 783 666 -14.9% 2,256 1,850 -18.0%
    Finished goods 12 22 93.0% 43 55 26.5%
    Staff cost 182 217 19.2% 527 617 17.1%
    Advertising 194 250 28.9% 535 602 12.4%
    Other exps 554 454 -18.0% 1,502 1,200 -20.1%
    Patent and trademark 12 25 99.2% 37 61 66.6%
    Def. Rev. exps. 13 13 0.0% 37 37 0.8%
    Total 1,744 1,844 5.7% 4,836 4,504 -6.9%

    Please note for the comparision on a YoY basis, we have taken numbers that had been stated by the management last year. The company seems to have restated some numbers, as a result of which the bottomline dip during September quarter is coming to 12.3% (as opposed to 15% shown in the table). We haven't received the company's press release and consequently, are showing the comparision based on the numbers made available last year.

    The poor results in June quarter had shaken investor confidence towards the counter. GlaxoSmithKline Consumer anyway never got higher valuations owing to its one product category focus. The parent's other 100% subsidiary was always a cause for concern. But the blip in quarterly results saw the stock price lose a significant market cap.

    The stock is trading at Rs 282, a P/E of 12.7x annualised 9mFY03 earnings. Though the performance has brought some relief to investors, a full fledged recovery in the company's fortunes seems still some time away. The company's statement: "Due to the recessionary trends still prevailing in the malted food industry the capacity utilisation of the plant (Sonepat) has been below the forecast level", gives an indication of the difficult market conditions for SBCH. Having said that, GlaxoSmithKline Consumer has traditionally had a stable business growth and on the longer term we remain positive on the company's progress.

     

     

    Equitymaster requests your view! Post a comment on "SBCH: Improvement signs…". Click here!

      
     

    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    Apex frozen food Ltd. (IPO)

    Aug 21, 2017

    Should you subscribe to the IPO of Apex Frozen Foods Ltd?

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK CONSUMER SHARE PRICE


    Aug 23, 2017 09:51 AM

    TRACK GSK CONSUMER

    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK CONSUMER - NESTLE COMPARISON

    Compare Company With Charts

    COMPARE GSK CONSUMER WITH

    MARKET STATS